Unveiling sarcopenia prevalence in post-cancer patients: Integrating functional and morphological assessments for accurate diagnosis - 02/07/26
Highlights |
• | Sarcopenia remains underdiagnosed in younger post-cancer patients. |
• | Prevalence assessed in 98 patients from the JUMP post-cancer cohort. |
• | EWGSOP2-defined sarcopenia identified in 28% of participants. |
• | Functional tests and DXA effectively detect sarcopenia. |
• | Sarcopenia is frequent in cancer survivors regardless of age. |
Abstract |
Objectives |
Sarcopenia is a muscle disease characterized by the progressive loss of muscle mass, strength, and function. Despite evolving definitions, validated diagnostic tools for younger individuals, especially those with cancer or chronic diseases, remain lacking. Oncological treatments can lead to severe muscle deconditioning. Many patients face limited follow-up and remain physically diminished in post-cancer period. We aimed to determine the prevalence of sarcopenia in post-cancer patients and to highlight its occurrence even in younger individuals and long after completion of oncological treatments.
Methods |
We performed prospective and standardized muscle assessment through: physical activity questionnaires (International Physical Activity Questionnaire [IPAQ] and Strength, Assistance with walking, Rise from a chair, Climb stairs and Falls [SARC-F]); functional tests (grip strength, 6-minute walk, and 30-second chair stand tests); and appendicular lean mass (ALM) index measurement by dual-energy X-ray absorptiometry (DXA; ALM/height 2 in kg/m 2 ).
Results |
Ninety-eight patients (68 females) were included (age (mean ± SD) 53.8 ± 11.0 years and body mass index (BMI) 27.8 ± 6.4 kg/m 2 ). Fifty-five had solid tumors (41 metastatic) with a post-treatment duration of 20.3 ± 21.75 months. SARC-F score was 1.5 ± 1.6. Grip strength and ALM index were 27.3 ± 11.7 kg and 6.4 ± 1.4 kg/m 2 respectively. Considering cancer as a sarcopenia at risk status, we used European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria and identified 27 (27.6%) patients with sarcopenia. Patients with sarcopenia were younger (50.2 ± 11.6 vs 55.2 ± 12.0 years; P = 0.07), more frequently in remission and long after treatment, and had lower BMI (23.3 ± 3.2 vs 29.5 ± 6.5 kg/m 2 ; P < 0.0001) compared to patients without sarcopenia. When using SARC-F for screening, only 5 patients were detected, underlining its poor sensitivity in this setting.
Conclusion |
Sarcopenia is highly prevalent in post-cancer patients including younger individuals and those in long-term remission. The 2019 EWGSOP2 criteria, combining ALM and functional tests, effectively identified sarcopenia but screening with SARC-F may not be suitable in the post-cancer population.
Le texte complet de cet article est disponible en PDF.Keywords : Sarcopenia, Post-cancer, EWSGOP2, Muscle mass, Muscle strength, Muscle deconditioning, Classification, After effects, SARC-F
Plan
Vol 93 - N° 4
Article 106022- juillet 2026 Retour au numéro
Article précédent
- AA amyloidosis in inflammatory joint diseases in the era of biological therapies: Prevalence, manifestations, management and evolution
- Anna Raymond, Binta Savadogo, Rim Bourguiba, Azeddine Dellal, David Buob, Léa Savey, Gilles Grateau, Morgane Assaraf, Jean-Jacques Boffa, Alexandre Cez, Pierre-Antoine Michel, Jérémie Sellam, Sophie Georgin-Lavialle, Bruno Fautrel, Stéphane Mitrovic
- Mechanistic study of fibroblast-derived extracellular vesicle miR-25-3p targeting TAF15 to inhibit NF-κB activation and alleviate knee osteoarthritis progression in mice
- Jianhang Wang, Mingfu Fu, Bo Cong, Mingqi Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?